Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

To determine whether short-term pre-operative nivolumab either as monotherapy or in combination with low dose doxorubicin or novel IO combinations can induce immune activation in early BC.

Trial Details

NCT ID
NCT03815890
Phase
PHASE2
Sponsor
The Netherlands Cancer Institute
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Nivolumab
  • Ipilimumab
Locations (sample)
  • Amsterdam, Netherlands|52.37403,4.88969

Key Eligibility Criteria

  • Signed written informed consent
  • 18 years or older at moment of inclusion;
  • Female gender;
  • WHO performance status 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →